Loading clinical trials...
Loading clinical trials...
An Open-Label Study to Investigate the Pharmacodynamics of a Repeat Dose Regimen of Bevacizumab (10 mg/kg q2w) and Escalating Repeat Doses of Pazopanib in Renal Cell Carcinoma
Conditions
Interventions
Bevacizumab
Pazopanib 2 week
+1 more
Locations
1
United Kingdom
GSK Investigational Site
Cambridge, Cambridgeshire, United Kingdom
Start Date
November 18, 2009
Primary Completion Date
November 1, 2013
Completion Date
November 1, 2013
Last Updated
November 13, 2017
NCT07227415
NCT05127824
NCT05865730
NCT05239728
NCT04028245
NCT04338269
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions